Petros Pharmaceuticals, Inc. Finite-Lived Intangible Asset, Expected Amortization, Year One
Petros Pharmaceuticals, Inc. (PTPI) had Finite-Lived Intangible Asset, Expected Amortization, Year One of $747.52 thousand as of 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths · last filed 2025-03-31
- 2024-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $747.52K.
- 2024-09-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $1.75M.
- 2024-06-30: Finite-Lived Intangible Asset, Expected Amortization, Year One $1.75M.
- 2024-03-31: Finite-Lived Intangible Asset, Expected Amortization, Year One $1.75M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year One |
|---|---|
| 2024-12-31 | $747.52K 10-K · filed 2025-03-31 |
| 2024-09-30 | $1.75M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $1.75M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $1.75M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $2.80M 10-K · filed 2024-04-01 |
| 2023-09-30 | $2.80M 10-Q · filed 2023-11-15 |
| 2023-06-30 | $2.80M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $2.80M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $3.27M 10-K · filed 2023-03-31 |
| 2022-09-30 | $3.27M 10-Q/A · filed 2022-11-15 |
| 2022-06-30 | $5.45M 10-Q · filed 2022-08-12 |
| 2022-03-31 | $5.45M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $6.19M 10-K · filed 2022-03-31 |
| 2021-09-30 | $6.19M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $6.19M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $6.19M 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B |